Futura Medical hails positive phase III results as it prepares for US FDA sign-off for ED gel

Futura Medical’s Ken James talked to Proactive about the next steps on the journey to obtaining US Food & Drug Administration marketing authorisation for its breakthrough erectile dysfunction gel (ED), MED3000.

This follows the successful completion of a phase III study of the treatment, which showed it as being effective, safe and having no serious side effects.

The company believes MED3000, which takes just 10 minutes to work, has the potential to be America’s first over-the-counter treatment for ED.

#erectiledysfunction #futuramedical #aim #biotechnology #fda

© 2022 Stockmark.it The Latest StockMarket News and Interviews